We demonstrated that TRPV2 was overexpressed in cancer stem cells derived from ESCC, and suggested the potential of tranilast, a TRPV2-specific inhibitor, as a therapeutic agent for cancer stem cells17. Here, TRPV2 is linked to esophageal squamous cell carcinoma.